TAK‑653 (Osavampator)
Experimental antidepressant candidate (AMPA enhancer) that met its main goal in a phase 2 human trial; not yet approved.
Pharmacology
Contents
DETAILED OVERVIEW
What is TAK-653 (Osavampator)?
TAK-653 (osavampator) is an experimental drug candidate developed by the pharmaceutical company Takeda and studied against depression. It is not approved anywhere: in the USA it is in clinical development, and in the European Union it counts as a research chemical and is not on the market.
It strengthens the AMPA receptor, one of the receiving proteins for glutamate, the brain's stimulating messenger, but only where nerve cells are already signaling. In animal studies this led to a fast, ketamine-like antidepressant effect, without ketamine's intoxicating, mind-altering effects. It was well tolerated in healthy volunteers, and in a phase 2 trial it met its main goal as an add-on treatment for depression; development continues in phase 3. Headache was the most commonly reported problem, and in theory overstimulation and, in people prone to epilepsy, seizures are possible. There is no safety data for pregnancy and breastfeeding.
Mechanism
AMPA-PAM (glutamate-dependent)
Half-life
33-48 hours
Onset
Hours (acute cortical), weeks (antidepressant)
Legal status
Investigational, Phase 3, not approved anywhere
Developer communications and research reports describe TAK-653 as a "clean" AMPA modulator that amplifies the brain's own signals and only steps in at active synapses, thereby avoiding the seizure risk of older ampakines. Research data link it to strengthened long-term potentiation and rising BDNF levels, with a ketamine-like antidepressant direction but without dissociation. In healthy volunteers the psychostimulant-type effect was milder than that of classic stimulants, with no serious adverse effects. A recurring observation is the inverse dose-response, where the lower dose outperformed the higher one, along with occasional overstimulation and headache; caution is advised with a personal or family history of epilepsy/seizures, or when combining with other strong glutamatergic or stimulant compounds. Long-term safety is not yet fully known, so this is a promising research compound rather than an established agent.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- AMPA receptorStrong
- BDNF / synaptic responseModerate
- Long-term potentiation (LTP)Moderate
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Overstimulation, agitation from amplified glutamatergic (AMPA) signaling
- Headache (the most commonly reported unpleasant effect)
- Sleep disturbance, heightened alertness if dosed late in the day
- Theoretical seizure/convulsion risk in those predisposed to epilepsy (though the preclinical safety margin is wide and no convulsions occurred in human studies)
- Limited human safety data: investigational, unapproved compound, full side-effect spectrum still unknown
- Long half-life (33-48 h) gives a cumulative effect, steady state over several days
Contraindications · 4
- Personal or family history of epilepsy/seizures (theoretical risk from glutamatergic potentiation)
- Avoid combining with other strong glutamatergic or stimulant compounds (overstimulation risk)
- Pregnancy and breastfeeding: no clinical safety data, avoid
- Not an approved drug, investigational; not recommended for self-treatment of major depression without clinical supervision
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats
Hara H, Suzuki A, Kunugi A, et al.
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers
Dijkstra F, et al.
Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
Suzuki A, et al.
TAK-653 Reverses Core Depressive Symptoms in Chronic Stress-Induced Monkey Model
Li L, et al.
FAQ
FAQ
TAK-653 is a drug candidate being developed by Takeda for depression, and it already hit its target goal in an early-stage human trial. It works by boosting brain signaling pathways that are already active, aiming for a fast, ketamine-like mood lift without the dissociative, mind-altering side effects. It has also shown cognitive-sharpening effects in studies and looked safe so far, but it is still in research/clinical trials, not an available product.
Telegram
Have a question about TAK‑653 (Osavampator)?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.